T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

~5 mi. (Burlington, North Carolina, +576 more cities)

Cone Health Cancer Center at Alamance Regional

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~5 mi. (Burlington, North Carolina, +744 more cities)

Cone Health Cancer Center at Alamance Regional

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

~5 mi. (Burlington, North Carolina, +656 more cities)

Cone Health Cancer Center at Alamance Regional

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Colon Adenocarcinoma, +1 more condition

atezolizumab, +3 more drugs

chemotherapy, +1 more type

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

~5 mi. (Burlington, North Carolina, +497 more cities)

Cone Health Cancer Center at Alamance Regional

HER2 Positive

Breast Adenocarcinoma

atezolizumab, +4 more drugs

chemotherapy, +2 more types

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

~5 mi. (Burlington, North Carolina, +822 more cities)

Cone Health Cancer Center at Alamance Regional

ER Negative, +2 more biomarkers

Invasive Breast Carcinoma

carboplatin, +3 more drugs

chemotherapy

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

~5 mi. (Burlington, North Carolina, +954 more cities)

Cone Health Cancer Center at Alamance Regional

Non-Small Cell Lung Carcinoma

crizotinib, +4 more drugs

chemotherapy, +2 more types

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

~5 mi. (Burlington, North Carolina, +388 more cities)

Cone Health Cancer Center at Alamance Regional

Small Cell Lung Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +2 more types

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

~5 mi. (Burlington, North Carolina, +577 more cities)

Cone Health Cancer Center at Alamance Regional

Non-Small Cell Lung Carcinoma

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

~5 mi. (Burlington, North Carolina, +263 more cities)

Cone Health Cancer Center at Alamance Regional

TMB-High

Glioblastoma

ipilimumab, +1 more drug

immunotherapy

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

~5 mi. (Burlington, North Carolina, +923 more cities)

Cone Health Cancer Center at Alamance Regional

ALK Fusion

Non-Small Cell Lung Carcinoma

crizotinib

targeted therapy

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

~5 mi. (Burlington, North Carolina, +253 more cities)

Cone Health Cancer Center at Alamance Regional

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

~22 mi. (Greensboro, North Carolina, +196 more cities)

Medication Management, LLC

Prostate Adenocarcinoma

anti-androgen therapy, +1 more drug

hormone therapy